Therapeutic implications of 14-3-3 zeta protein in rheumatoid arthritis
Candost Sarıçoban1
, Gizem Yağmur Aydoğdu2, Oytun Erbaş3
1Biruni Üniversitesi, Faculty of Medicine, İstanbul, Türkiye
2Atılım Üniversitesi, Faculty of Medicine, Ankara, Türkiye
3Institute of Experimental Medicine, Gebze-Kocaeli, Türkiye
Keywords: 14-3-3 zeta, bone loss, interleukin-1beta, rheumatoid arthritis, vaccine.
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint destruction accompanied by inflammatory, systemic complications. Its chronic and progressive course severely affects the quality of life of patients. Recent animal studies have shown that the application of 14-3-3 zeta (14-3-3ζ) during the pre-symptomatic phase through active immunological function suppresses pro-inflammatory cytokines such as interleukin-1beta, while increasing the anti-inflammatory interleukin-1 receptor antagonist levels and collagen synthesis, thus preserving joint and bone quality. However, when anti-14-3-3ζ antibodies were applied through passive immunization, the same effect was not observed. These findings suggest that the 14-3-3 protein family may be used in the diagnosis and treatment of RA and has significant potential. This review examines the pathophysiology of RA, the multifunctionality of the 14-3-3 protein family, and the therapeutic potential of 14-3-3ζ.
Cite this article as: Sarıçoban C, Yağmur Aydoğdu G, Erbaş O. Therapeutic implications of 14-3-3 zeta protein in rheumatoid arthritis. D J Tx Sci 2024;9(1-2):27-33. doi: 10.5606/dsufnjt.2024.22.